Delving into the Latest Updates on Royan Institute with Synapse

The Efficacy of Autologous Testicular Platelet Rich Plasma (PRP) for Patients with a History of Microdissection Testicular Sperm Extraction (mTESE) Failure: Clinical Trial

开始日期2024-02-20

申办/合作机构

Royan Institute

[+1]

NCT06199024 / RecruitingN/AIIT

The Effect of Cinnamon Supplementation on Infertility Treatment Outcomes in Infertile Women With Polycystic Ovary Syndrome (PCOS) Candidate of in Vitro-fertilization (IVF): A Pilot Double Blind Randomized Controlled Clinical Trial

In patients with polycystic ovary syndrome, insulin resistance increases, and since the extracts from cinnamon reduces insulin resistance by two mechanisms (1- increasing activation of the IRS/PI-3 kinase insulin signaling pathway and 2- stimulate auto phosphorylation of the insulin receptor and inhibit protein tyrosine phosphatase I). Through these two mechanisms cinnamon extract make adipocytes to increase the glucose uptake and glycogen synthesis. So this hypothesis arises that it can be effective in improving the symptoms of polycystic ovary syndrome.

开始日期2023-11-21

申办/合作机构

Royan Institute

IRCT20170122032121N7 / Recruiting临床2期

Efficacy of the intrathecal injection of activated allogeneic natural killer cells in patients with High-grade gliomas; A multi-center phase II clinical trial

开始日期2023-06-22

申办/合作机构

Royan Institute

100 项与 Royan Institute 相关的临床结果

登录后查看更多信息

0 项与 Royan Institute 相关的专利（医药）

登录后查看更多信息

2,534

项与 Royan Institute 相关的文献（医药）

2024-12-01·Colloids and Surfaces B: Biointerfaces

Incorporation of calcium phosphate cement into decellularized extracellular matrix enhances its bone regenerative properties

Article

作者: Kalantari, Niloofar ; Raminfard, Samira ; Alibeigian, Yalda ; Baghaban Eslaminejad, Mohamadreza ; Kamali, Amir ; Ebrahimi Sadrabadi, Amin ; Hosseini, Samaneh

Decellularized extracellular matrix (dECM) hydrogels are engineered constructs that are widely-used in the field of regenerative medicine. However, the development of ECM-based hydrogels for bone tissue engineering requires enhancement in its osteogenic properties. For this purpose, we initially employed bone-derived dECM hydrogel (dECM-Hy) in combination with calcium phosphate cement (CPC) paste to improve the biological and structural properties of the dECM hydrogel. A decellularization protocol for bovine bone was developed to prepare dECM-Hy, and the mechanically-tuned dECM/CPC-Hy was built based on both rheological and mechanical characteristics. The dECM/CPC-Hy displayed a double swelling ratio and compressive strength. An interconnected structure with distinct hydroxyapatite crystals was evident in dECM/CPC-Hy. The expression levels of Alp, Runx2 and Ocn genes were upregulated in dECM/CPC-Hy compared to the dECM-Hy. A 14-day follow-up of the rats receiving subcutaneous implanted dECM-Hy, dECM/CPC-Hy and mesenchymal stem cells (MSCs)-embedded (dECM/CPC/MSCs-Hy) showed no toxicity, inflammatory factor expression or pathological changes. Radiography and computed tomography (CT) of the calvarial defects revealed new bone formation and elevated number of osteoblasts-osteocytes and osteons in dECM/CPC-Hy and dECM/CPC/MSCs-Hy compared to the control groups. These findings indicate that the dECM/CPC-Hy has substantial potential for bone tissue engineering.

2024-12-01·Regenerative Therapy

Enriched human embryonic stem cells-derived CD133+, CD24+ renal progenitors engraft and restore function in a gentamicin-induced kidney injury in mice

Article

作者: Moghadasali, Reza ; Azimi, Masoumeh ; Saber, Maryam ; Abbaszadeh, Hojjat Allah ; Serra, Andreas L ; Bakhtiyari, Mohsen ; Abdollahifar, Mohammad-Amin ; Roozbahany, Navid Ahmady ; Bahrami, Maryam ; Norouzian, Mohsen ; Ehsani, Ehsan

IntroductionAcute kidney injury (AKI) is a common health problem that leads to high morbidity and potential mortality. The failure of conventional treatments to improve forms of this condition highlights the need for innovative and effective treatment approaches. Regenerative therapies with Renal Progenitor Cells (RPCs) have been proposed as a promising new strategy. A growing body of evidence suggests that progenitor cells differentiated from different sources, including human embryonic stem cells (hESCs), can effectively treat AKI.MethodsHere, we describe a method for generating RPCs and directed human Embryoid Bodies (EBs) towards CD133+CD24⁺ renal progenitor cells and evaluate their functional activity in alleviating AKI.ResultsThe obtained results show that hESCs-derived CD133+CD24⁺ RPCs can engraft into damaged renal tubules and restore renal function and structure in mice with gentamicin-induced kidney injury, and significantly decrease blood urea nitrogen levels, suppress oxidative stress and inflammation, and attenuate histopathological disturbances, including tubular necrosis, tubular dilation, urinary casts, and interstitial fibrosis.ConclusionThe results suggest that RPCs have a promising regenerative potential in improving renal disease and can lay the foundation for future cell therapy and disease modeling.

2024-11-01·Current Reviews in Clinical and Experimental Pharmacology

Advanced Therapeutic Medicinal Products in Bone and Cartilage Defects

Review

作者: Shpichka, Anastasia ; Vosough, Massoud ; Peshkova, Maria ; Smirnova, Olga ; Shams, Roshanak ; Sadri, Bahareh ; Diaz-Solano, Dylana ; Timashev, Peter

Abstract:The number of patients with functional loss of bone and cartilage tissue has shown an increasing trend. Insufficient or inappropriate conventional treatments applied for trauma, orthopedic diseases, or other bone and cartilage-related disorders can lead to bone and cartilage damage. This represents a worldwide public health issue and a significant economic burden. Advanced therapeutic medicinal products (ATMPs) proposed promising alternative therapeutic modalities by application of cell-based and tissue engineering approaches. Recently, several ATMPs have been developed to promote bone and cartilage tissue regeneration. Fifteen ATMPs, two related to bone and 13 related to cartilage, have received regulatory approval and marketing authorization. However, four ATMPs were withdrawn from the market for various reasons. However, ATMPs that are still on the market have demonstrated positive results, their broad application faced limitations. The development and standardization of methodologies will be a major challenge in the coming decades. Currently, the number of ATMPs in clinical trials using mesenchymal stromal cells or chondrocytes indicates a growing recognition that current ATMPs can be improved. Research on bone and cartilage tissue regeneration continues to expand. Cell-based therapies are likely to be clinically supported by the new ATMPs, innovative fabrication processes, and enhanced surgical approaches. In this study, we highlighted the available ATMPs that have been used in bone and cartilage defects and discussed their advantages and disadvantages in clinical applications.

100 项与 Royan Institute 相关的药物交易

登录后查看更多信息

100 项与 Royan Institute 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

临床1期

临床2期

1

6

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Bone marrow mesenchymal stromal cells-derived extracellular vesicles(Royan Institute)	原发性卵巢功能不全更多	临床2期
Allogenic Natural Killer cells(Royan Institute)	脑癌更多	临床1期
CD19CAR-MC (Royan Institute) ( CD19 )	白血病更多	临床前
AC-133(Royan Institute)	急性心肌梗塞更多	无进展
Limbal Stem Cell Transplantation(Sun Yat-sen University)	畏光更多	无进展